Merck and Moderna Pioneer Personalized Cancer Treatment with mRNA Technology

Scientists are shifting their approach to cancer treatment from one-size-fits-all to personalized care. By learning about the genetic makeup of each person's tumor, researchers can identify unique differences and develop targeted therapies.

Merck and Moderna are collaborating on an individualized neoantigen therapy (INT) that trains a patient's immune system to recognize and destroy cancer cells. This approach uses mRNA technology to create a customized treatment for each patient's specific biology.

Researchers are currently conducting studies to better understand how INTs can enhance immune surveillance against cancer. Dr. Vassiliki Karantza, Associate Vice President of Global Clinical Development at Merck Research Laboratories, stated that 'because the genetic makeup of a patient's cancer is unique to that person, we believe there is a need for innovative therapies that can be tailored to a patient's tumor.'

Dr. Michelle Brown, Head of Oncology Portfolio Development at Moderna, added that this approach could represent a shift toward more personalized care in cancer, where therapies are designed based on each patient's specific biology.